期刊文献+

HPLC测定雷诺嗪缓释片的含量及有关物质 被引量:1

Determination of related substance and content in Ranolazine-sustained release tablets by HPLC
原文传递
导出
摘要 目的采用HPLC测定雷诺嗪缓释片的含量和有关物质。方法采用Inertsil C18色谱柱(250 mm×4.6 mm,5μm),流动相为乙腈-0.02 mol·L-1磷酸二氢钾-三乙胺(52∶48∶0.1),流速1.0 mL·min-1,检测波长230 nm。结果雷诺嗪与中间体Ⅰ及其降解产物能有效分离,雷诺嗪20.24~506.00μg·mL-1与峰面积线性关系良好(r=0.9999,n=5),平均回收率为99.89%(RSD=0.61%,n=9),检测限为0.5 ng,中间体Ⅰ对雷诺嗪的相对保留时间约为0.25,相对响应因子约为1.25。结论所用方法简便、准确、重复性、专属性及灵敏度好,可用于雷诺嗪缓释片中有关物质和含量的测定。 OBJECTIVE To establish an HPLC method to determine the related substance and content in Ranolazine-sustained release tablets.METHODS Inertsil C18 column(250 mm×4.6 mm,5 μm)served as the solid phase,and acetonitrile-0.02 mol·L-1 potassium dihydrogen phosphate-triethylamine(52:48:0.1) was used as the mobile phase.The flow rate was 1.0 mL·min-1,and the detection wavelength was 230 nm.RESULTS Ranolazine and its related substance could be separated effectively.There was a good linear relationship between the peak area and the concentration in the range of 20.24-506.00 μg·mL-1(r=0.9999,n=5).The average recovery was 99.89%(RSD=0.61%,n=9),and the LOD was 0.5 ng.The relative retention time between intermediatesⅠ and ranolazine was about 0.25,and the relative response factors was about 1.25.CONCLUSION The method is simple,specific,sensitive and suitable for the determination of related substance and content in Ranolazine-sustained release tablets.
出处 《华西药学杂志》 CAS CSCD 北大核心 2012年第3期318-320,共3页 West China Journal of Pharmaceutical Sciences
关键词 高效液相色谱法 雷诺嗪 有关物质 含量 HPLC Ranolazine Related substance Content
  • 相关文献

参考文献3

  • 1苗佩宏,徐江平.新型抗心绞痛药物雷诺嗪的研究进展[J].国外医学(药学分册),2003,30(4):197-200. 被引量:17
  • 2中华人民共和国国家药典委员会.中国药典[s].二部:北京:中国医药科技出版社,2010:附录ⅣA.
  • 3国家食品药品监督管理局药品审评中心.化学药物研究技术指导原则[S].2005.

二级参考文献20

  • 1Schofield RS, Hill JA. The uee of ranolazine in cardiovascular disease[J].Expert Opin Investig Drugs,2002,11(1):117-123
  • 2Wolff AA, Rotmensch HH.Metabolic approaches to the treatment of ischemic heart disease:the clinicians'perspective[J].heart Fail Rev,2002,7(2):187-203
  • 3McCormack JG, Barr RL.Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts[J]. Circulation, 1996, 93(1):135- 142.
  • 4Clarke B, Wyatt KM, McCormack JG.Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism[J]. J Mol Cell Cardiol, 1996, 28(2):341-350.
  • 5Allen TJ,Chapman RA.Effects of ranolazine on L-type calcium channel currents in guinea-pig single wentricular myocytes[J].Br J Pharmacol,1996,118(2):249-254
  • 6Letienne R,Vie B,Puech A,et al.Evidence that ranolazine behaves as a weak β1-and β2-adrenoceptor antagonist in the cat cardiovascular system[J].Naunyn Schmiedebergs Arch Pharmacol,2001,363(4):464-471
  • 7Wang JX,Maruyama K,Murakami M,et al.Antianginal effects of ranolazine in various experimental models of angina[J].Arzneimittelforschung,1999,49(3):193-199
  • 8Sabbah HN,Chandler MP,Mishima T,et al.Ranolazine,a partial fatty acid oxidation(pFOX)inhibitor,improves left ventricular function in dogs with chronic heart failure[J].J Card Fail,2002,8(6):416-422
  • 9Chandler MP,Stanley WC,Morita H,et al.Short-sterm treatment with ranolazine improves mechanical effciency in dogs with chronic heart failure[J].Circ Res,2002,91(4):278-280
  • 10?AMorin D,Hauet T,Spedding M,et al.Mitocbondria as target for antiischemic drugs[J].Adv Drug Deliv Rev,2001,49(1/2):151-174

共引文献17

同被引文献5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部